Tiamaes(SZ:300807) Mei Ri Jing Ji Xin Wen·2025-10-24 11:27Company Performance - Tianmai Technology (SZ 300807) reported third-quarter results with revenue of approximately 87.69 million yuan for the first three quarters of 2025, representing a year-on-year increase of 57.08% [1] - The company recorded a net loss attributable to shareholders of approximately 15.35 million yuan, with basic earnings per share showing a loss of 0.23 yuan [1] - As of the report date, Tianmai Technology has a market capitalization of 2.7 billion yuan [1] Industry Insights - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year [1] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is experiencing a cooling in fundraising [1]